Argentina Antacids Market Overview, 2031

Key Insights

• According to the research report, "Argentina Antacids Market Outlook, 2031," published by Bonafide Research, the Argentina Antacids Market is anticipated to grow at more than 5.15% CAGR from 2026 to 2031.
• The baseline demand for antacids and acid-suppression remedies in Argentina is among the highest in Latin America, primarily fueled by local dietary and lifestyle factors. Latin American epidemiological consensus studies highlight that Argentina has one of the highest GERD symptom rates globally, with approximately 23% of the adult population experiencing weekly typical GERD symptoms (heartburn and regurgitation). A high consumption of beef, late-night dining practices, and heavy intake of acidic/tannin-rich beverages (such as mate and wine) lead to high rates of episodic hyperacidity and postprandial distress, maintaining year-round retail demand for fast-acting antacids.
• Argentina’s OTC self-medication culture leans heavily toward immediate, short-acting symptom relief for episodic heartburn. Product innovation in Argentina focuses on dual-action alginate-antacid suspensions and rapid-dissolve effervescent salts. Modern alginate formulations create a protective physical raft over gastric contents while buffering acid, providing immediate defense against esophageal irritation.
• Hyperinflation and macroeconomic volatility in Argentina have significantly impacted drug pricing, consumer purchasing behavior, and healthcare channel distribution. Rising costs for prescription healthcare have prompted consumers to increasingly turn to OTC self-medication options as a first-line, cost-effective alternative to physician visits. Community pharmacies (farmacias) play a pivotal role in brand selection. Pharmacists in Argentina act as key advisors, often guiding cost-conscious consumers toward affordable, locally manufactured OTC antacids, chewables, and alginates over more expensive prescription-tier alternatives.

Market Outlook

• To cater to busy urban lifestyles across major metro areas like Buenos Aires and Córdoba, manufacturers are expanding convenient single-dose liquid sachets and portable blister-packed chewables that do not require water. This form factor shift is expected to capture higher retail margins in impulse pharmacy purchases.
• Aligning with rising consumer interest in natural self-care, future product lines in Argentina are expected to feature hybrid OTC remedies combining fast-acting mineral neutralizers with natural gastric-soothing ingredients (such as chamomile, boldo, or artichoke extracts) to promote long-term digestive comfort alongside acute acidity relief.
• The market operates under regulatory frameworks set by ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) alongside guidance from the SAG (Sociedad Argentina de Gastroenterología) and COFA (Confederación Farmacéutica Argentina), with supply led by major domestic and international pharmaceutical companies including GlaxoSmithKline / Haleon (Uvasal), Bayer (Alka-Seltzer, Rennie), Johnson & Johnson / Kenvue (Mylanta variants), Laboratorios Elea Phoenix, and Elea / Roemmers Group.

Market Dynamics

Driver: Recovery in consumer spending and continued self-medication demand
A key driver for Argentina's antacids market is the expected improvement in consumer purchasing power and confidence, which should support spending on OTC digestive remedies. Euromonitor reports that digestive-remedy sales increased in current-value terms in 2025 and expects demand to continue rising as the economic environment improves. Most adult digestive-remedy categories are expected to achieve positive retail-volume growth as consumer confidence recovers.
Challenge: Substitution from PPIs and other digestive remedies
A primary bottleneck facing Argentine biomanufacturers is navigating macroeconomic fluctuations and import restrictions when acquiring specialized medical-grade raw polymers (e.g., multi-layer EVOH and low-density polyethylene). Because raw film extrusions and pre-assembled bag manifolds are predominantly imported from North America and Europe, local companies face supply chain delays and currency volatility. Additionally, qualifying foreign film integrity to meet ANMAT (Administración Nacional de Medicamentos, Alimentos y Tecnología Médica) guidelines for Extractables and Leachables (E&L) requires high analytical testing expenditure. The competitive pressure is important because consumers experiencing recurring reflux may prefer products perceived to provide stronger or longer-lasting acid suppression rather than traditional acid-neutralizing antacids. At the same time, digestive enzymes and herbal remedies are also gaining consumer interest.
Trend: Shift toward natural/herbal digestive products and broader gut-health positioning
A notable trend is the growing consumer interest in herbal and natural digestive remedies. Euromonitor expects herbal digestive remedies to remain robust as Argentine consumers increasingly seek products perceived as natural and free from artificial or chemical additives. For example, Laboratorio Elea introduced Hepatalgina 9 Herbs in February 2024, positioned for temporary relief of stomach pain, bloating, flatulence and colic. This trend is part of a broader movement toward preventive and holistic digestive health. Euromonitor also reports growing interest in probiotics and other supplements, with probiotics expected to benefit from increasing awareness of digestive and stress-related health concerns.

Segment Analysis

Argentina Antacids Market By Drug Class • Acid neutralizers remain closely associated with rapid, on-demand relief in Argentina because they act directly on gastric acid already present in the stomach. Calcium carbonate, magnesium hydroxide and aluminium-containing preparations support this segment, particularly for occasional heartburn and acid indigestion. Their accessibility is reinforced by Argentina's regulatory framework, which specifically permits non-pharmacy establishments authorized to sell OTC medicines to market antacids.
• Proton Pump Inhibitors (PPIs) occupy a more sustained acid-control position because they suppress gastric acid production rather than neutralizing existing acid. Their role is particularly relevant for recurring reflux and other acid-related conditions where consumers move beyond occasional symptomatic treatment. Argentina has also been progressively expanding OTC access to PPIs: ANMAT reports that prazoles were among the active ingredients moved to OTC status as part of its broader reassessment of medicine dispensing conditions.
• H2 antagonists provide an intermediate acid-suppression approach by blocking histamine-mediated gastric acid secretion. They can appeal to consumers seeking longer symptom control than conventional antacids without necessarily using a PPI. Their competitive position is influenced by the increasing availability and familiarity of alternative acid-suppressive therapies in Argentina.
• Pro-motility agents form a more specialized segment because they address gastrointestinal movement and gastric emptying rather than directly neutralizing stomach acid. Their relevance increases when reflux-like symptoms coexist with bloating, early satiety or suspected motility disturbances. Consequently, this class is more closely connected with clinically directed gastrointestinal management than with straightforward antacid self-treatment.
• Combination formulations are particularly relevant for consumers who experience acidity together with gas, indigestion or reflux. Combining an acid neutralizer with alginate, simethicone or another gastrointestinal ingredient allows manufacturers to position products around multiple symptoms rather than acidity alone. This approach can be valuable in Argentina's mature self-medication environment, where product differentiation increasingly depends on convenience and broader symptom coverage.



Argentina Antacids Market By Dosage Form
• Tablets and chewables are highly compatible with Argentina's self-care environment because they are portable, convenient and provide clearly defined unit dosing. Chewables are particularly suited to consumers seeking relief after meals or while away from home. Their simplicity also makes them appropriate for direct consumer selection in pharmacies and other authorized OTC outlets.
• Liquid suspensions provide an important alternative for consumers who prefer liquids or have difficulty swallowing tablets. They can accommodate combinations of aluminium- and magnesium-based ingredients and allow flexible formulation. Accurate measuring, shaking requirements, flavour and physical stability remain important considerations for product acceptance.
• Powders provide a flexible dosage format that can be supplied in individual sachets or other convenient packaging. They can be designed for dissolution or dispersion before administration and may appeal to consumers seeking rapid preparation. However, the need to prepare the product creates a convenience trade-off compared with ready-to-use liquids and chewables.
• Gels and syrups emphasize smooth administration and can support formulations incorporating reflux-barrier ingredients such as alginates. Their texture can make them attractive to consumers who dislike solid medicines. Liquid and semi-solid products also allow manufacturers to differentiate through flavour, viscosity and sensory characteristics.
• Gummies and other formats represent a more modern consumer-oriented opportunity rather than the traditional core of Argentina's antacid category. Gummies can improve portability and palatability, although achieving adequate active-ingredient loading while maintaining an acceptable taste and texture can be challenging. Effervescent and rapidly dispersible products offer additional possibilities for convenience-focused innovation.

Argentina Antacids Market By Indication
• Gastroesophageal Reflux Disease (GERD) represents an important indication for acid-control products because recurrent reflux can move consumers from occasional antacid use toward H2 antagonists or PPIs. The treatment environment is increasingly differentiated according to symptom frequency and persistence, making rapid-relief products more relevant to occasional symptoms while sustained acid suppression becomes more appropriate for recurring disease.
• Heartburn is a major consumer-facing indication because it is readily recognizable and commonly treated without an immediate physician consultation. Argentine self-medication research illustrates the importance of gastrointestinal symptoms in this environment. A study from Comodoro Rivadavia found 9% of respondents identified antacids and digestive medicines among the main pharmacological groups used for self-medication.
• Peptic ulcer represents a more medically managed indication than routine heartburn. Antacids can provide symptomatic relief, but they do not eliminate underlying causes such as H. pylori infection or NSAID-related mucosal injury. PPIs and cause-directed treatment therefore have a more important role in ulcer management, while traditional antacids remain primarily positioned around short-term discomfort.
• Others include dyspepsia, acid indigestion, epigastric discomfort, gastritis-related symptoms, bloating and post-meal fullness. This segment is particularly relevant because consumers may use the broad concept of digestive problems rather than a specific medical diagnosis. In the Comodoro Rivadavia study, 9% of self-medication respondents reported antacids/digestive medicines among their main medication groups, reflecting the importance of symptom-led gastrointestinal self-care.

Argentina Antacids Market By Distribution Channel
• Retail pharmacies remain the most important channel because pharmacists can provide product-selection guidance while consumers obtain OTC gastrointestinal medicines. Argentine regulations allow OTC medicines to be displayed directly to consumers in pharmacies under specified conditions. This supports symptom-driven purchasing while maintaining requirements for packaging, prospect information and age restrictions.
• Hospital pharmacies serve a more clinically supervised segment involving patients with diagnosed GERD, peptic ulcers, severe gastrointestinal symptoms and other conditions requiring physician-directed treatment. Demand in this channel is therefore influenced more by clinical protocols and prescriptions than by spontaneous OTC purchases. PPIs and other acid-suppressive therapies are particularly relevant in this setting.
• Online pharmacies / E-commerce provide convenience for consumers seeking repeat purchases, price comparison and access to multiple brands and dosage forms. The channel can be especially useful for consumers already familiar with a particular antacid. However, medicine distribution remains subject to Argentina's regulatory framework and authorized sellers must comply with applicable medicine-storage, product and dispensing requirements.

Considered in this report
• Historic Year: 2020
• Base year: 2025
• Estimated year: 2026
• Forecast year: 2031

Aspects covered in this report
• Antacids Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Acid Neutralizers
• Proton Pump Inhibitors (PPIs)
• H2 Antagonists
• Pro-Motility Agents
• Combination Formulations

By Dosage Form
• Tablets & Chewables
• Liquid Suspensions
• Powders
• Gels & Syrups
• Gummies & Other

By Indication
• Gastroesophageal Reflux Disease
• Heartburn
• Peptic Ulcer
• Others

By Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies / E-Commerce